Allmed Medical Products Co.,Ltd (SHE:002950)
China · Delayed Price · Currency is CNY 10.03
-0.18 (-1.76%)
May 28, 2026, 3:04 PM CST
SHE:002950 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 3,769 | 3,632 | 3,293 | 2,707 | 4,195 | 2,888 |
Other Revenue | 40.03 | 40.03 | 33.12 | 49.4 | 15.78 | 37.44 |
| 3,809 | 3,672 | 3,326 | 2,757 | 4,211 | 2,926 | |
Revenue Growth (YoY) | 14.09% | 10.38% | 20.66% | -34.53% | 43.92% | -23.70% |
Cost of Revenue | 2,683 | 2,606 | 2,398 | 2,099 | 2,812 | 2,053 |
Gross Profit | 1,126 | 1,065 | 928.04 | 657.93 | 1,399 | 872.17 |
Selling, General & Admin | 376.87 | 366.61 | 374.65 | 386.38 | 446.53 | 367.52 |
Research & Development | 102.52 | 104.05 | 106.37 | 77.37 | 107.74 | 94.58 |
Other Operating Expenses | 30.09 | 17.81 | 10.49 | 13.82 | 26.47 | 19.13 |
Operating Expenses | 514.9 | 492.51 | 494.41 | 478.51 | 582.45 | 484.52 |
Operating Income | 611.5 | 572.63 | 433.64 | 179.42 | 816.21 | 387.65 |
Interest Expense | -17.38 | -17.67 | -25.53 | -31.87 | -35.47 | -17.18 |
Interest & Investment Income | 23.59 | 16.67 | 7.16 | 1.87 | 3.09 | 39.97 |
Currency Exchange Gain (Loss) | -11.62 | -11.62 | 17.15 | -8.57 | -140.63 | 33.41 |
Other Non Operating Income (Expenses) | -27.95 | -1.9 | -1.27 | -2 | -6.3 | -6.34 |
EBT Excluding Unusual Items | 578.14 | 558.11 | 431.15 | 138.85 | 636.9 | 437.51 |
Gain (Loss) on Sale of Investments | -280.54 | -268.88 | -23.28 | -6.88 | -160.19 | 6.13 |
Gain (Loss) on Sale of Assets | -2.56 | 0.77 | 28.79 | -0.07 | 3.5 | 1.94 |
Asset Writedown | -7.76 | -11.5 | -9.14 | 0.5 | -16.8 | -0.12 |
Other Unusual Items | 41.75 | 30.53 | 26.87 | 36.65 | 21.49 | 59.79 |
Pretax Income | 329.04 | 309.02 | 454.39 | 169.04 | 484.9 | 505.49 |
Income Tax Expense | 45.26 | 51.87 | 85.59 | 64.83 | 80.26 | 73.53 |
Earnings From Continuing Operations | 283.78 | 257.15 | 368.8 | 104.22 | 404.64 | 431.96 |
Minority Interest in Earnings | -12.45 | -8.26 | -0.12 | 6.18 | 2.15 | -0.75 |
Net Income | 271.33 | 248.88 | 368.68 | 110.4 | 406.79 | 431.21 |
Net Income to Common | 271.33 | 248.88 | 368.68 | 110.4 | 406.79 | 431.21 |
Net Income Growth | -24.90% | -32.49% | 233.95% | -72.86% | -5.66% | -62.75% |
Shares Outstanding (Basic) | 614 | 619 | 625 | 633 | 633 | 632 |
Shares Outstanding (Diluted) | 614 | 619 | 625 | 633 | 633 | 632 |
Shares Change (YoY) | -1.69% | -0.99% | -1.33% | 0.02% | 0.17% | -0.05% |
EPS (Basic) | 0.44 | 0.40 | 0.59 | 0.17 | 0.64 | 0.68 |
EPS (Diluted) | 0.44 | 0.40 | 0.59 | 0.17 | 0.64 | 0.68 |
EPS Growth | -23.61% | -31.82% | 238.44% | -72.87% | -5.82% | -62.73% |
Free Cash Flow | 285.83 | 456.81 | 554.64 | 137.02 | 751.68 | 84.16 |
Free Cash Flow Per Share | 0.47 | 0.74 | 0.89 | 0.22 | 1.19 | 0.13 |
Dividend Per Share | 0.146 | 0.146 | 0.060 | 0.027 | 0.060 | 0.210 |
Dividend Growth | 143.33% | 143.33% | 122.22% | -55.00% | -71.43% | -76.14% |
Gross Margin | 29.57% | 29.01% | 27.90% | 23.87% | 33.22% | 29.81% |
Operating Margin | 16.05% | 15.60% | 13.04% | 6.51% | 19.38% | 13.25% |
Profit Margin | 7.12% | 6.78% | 11.08% | 4.00% | 9.66% | 14.74% |
Free Cash Flow Margin | 7.50% | 12.44% | 16.68% | 4.97% | 17.85% | 2.88% |
EBITDA | 843.32 | 803 | 658.24 | 403.43 | 1,008 | 532.77 |
EBITDA Margin | 22.14% | 21.87% | 19.79% | 14.64% | 23.95% | 18.21% |
D&A For EBITDA | 231.82 | 230.37 | 224.6 | 224 | 192.2 | 145.12 |
EBIT | 611.5 | 572.63 | 433.64 | 179.42 | 816.21 | 387.65 |
EBIT Margin | 16.05% | 15.60% | 13.04% | 6.51% | 19.38% | 13.25% |
Effective Tax Rate | 13.76% | 16.79% | 18.84% | 38.35% | 16.55% | 14.55% |
Revenue as Reported | 3,809 | 3,672 | 3,326 | 2,757 | 4,211 | 2,926 |
Advertising Expenses | - | 22.47 | 17.97 | 15.98 | - | 27.1 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.